Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

Contributed by: PR Newswire

Tags

Rona-Raise-SeriesA

More Like This

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion

PR Newswire associated0

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

Novotech Report Reveals Growth in siRNA Research: Over 150 Industry-Sponsored Clinical Trials Conducted from 2020 to 2024